



Rely on **the only antidote** for the reversal of Eliquis® or Xarelto® in patients with acute major bleeding<sup>1</sup>

# SHUT OFF FXa INHIBITOR ACTIVITY WITH ANDEXXA<sup>1\*</sup>

\*In ANNEXA-A (n=31) and ANNEXA-R (n=39), randomized, double-blind, placebo-controlled studies in healthy volunteers, ANDEXXA bolus followed by continuous infusion reduced the primary endpoint of mean percent change in FXa inhibitor activity from baseline to nadir by 92% in Eliquis-treated subjects and 97% in Xarelto-treated subjects receiving low- and high-dose, respectively ( $P < 0.0001$ ).<sup>1,2</sup>

## **IMPORTANT SAFETY INFORMATION FOR ANDEXXA® (coagulation factor Xa [recombinant], inactivated-zhzo)**

### **WARNING: THROMBOEMBOLIC RISKS, ISCHEMIC RISKS, CARDIAC ARREST, AND SUDDEN DEATHS**

Treatment with ANDEXXA has been associated with serious and life-threatening adverse events, including:

- Arterial and venous thromboembolic events
- Ischemic events, including myocardial infarction and ischemic stroke
- Cardiac arrest
- Sudden deaths

Monitor for thromboembolic events and initiate anticoagulation when medically appropriate. Monitor for symptoms and signs that precede cardiac arrest and provide treatment as needed.

Please see additional Important Safety Information throughout and accompanying full Prescribing Information, including Boxed WARNING.

## **INDICATION**

ANDEXXA® (coagulation factor Xa [recombinant], inactivated-zhzo) is a recombinant modified human factor Xa (FXa) protein indicated for patients treated with rivaroxaban or apixaban, when reversal of anticoagulation is needed due to life-threatening or uncontrolled bleeding. This indication is approved under accelerated approval based on the change from baseline in anti-FXa activity in healthy volunteers. An improvement in hemostasis has not been established. Continued approval for this indication may be contingent upon the results of studies that demonstrate an improvement in hemostasis in patients.

## **Limitations of Use**

ANDEXXA has not been shown to be effective for, and is not indicated for, the treatment of bleeding related to any FXa inhibitors other than apixaban or rivaroxaban.

**Andexxa**<sup>®</sup>  
Coagulation Factor Xa  
(Recombinant), Inactivated-zhzo  
THE ONLY FXa INHIBITOR ANTIDOTE